Clinical TrialsSearch results
Number of results: 922
Other
- Phase III study of VCAP-AMP-VECP vs. biweekly CHOP in aggressive adult T-cell leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801.
- adult T-cell leukemia / lymphoma
- Japan Clinical Oncology Group(JCOG)
- 2005-08-17
Recruiting
- Single-center, open-label, single-arm study study to investigate efficacy and safety of Hydroxychloroquine in ATLL patients
- Adult T-Cell Leukemia-Lymphoma
- Amano Masahiro
- 2023-01-26
Completed
- Sequential combination therapy with CHOP and mogamulizumab in untreated primary ATLL patients
- adult T-cell leukemia-lymphoma
- Kato Koji
- 2019-03-18
Recruiting
- Autologous Dendritic Cell Vaccine Therapy Targeting HTLV-1 Specific Antigen for Adult T-Cell Leukemia/Lymphoma
- Adult T-Cell Leukemia/Lymphoma
- Suehiro Youko
- 2021-04-20
Recruiting
- TORG1938 (EPONA Study)
- Advanced / recurrent non-small cell lung cancer (NSCLC)
- Goto Yasushi
- 2020-09-01
Completed
- Uncommon EGFR mutations conducted with Osimertinib in patients with NSCLC: A phase 2 study
- Advanced / recurrent non-small cell lung cancer (NSCLC)
- Kubota Kaoru
- 2020-04-08
Completed
- A phase 2 study of osimertinib in elderly patients with non-small-cell lung cancer
- advanced / recurrent non-small cell lung cancer (NSCLC)
- Uchino Junji
- 2018-09-03
Other
- Phase I clinical trial of pan-HLA type personalized peptide vaccine for advanced cancer patients
- Advanced cancer patients who are refractory to standard therapies for cancer
- Department of Immunology, Kurume University School of Medicine
- 2007-03-01
Other
- randomized trial for the efficacy of primary prophylaxis with granulocyte colony stimulating factor in advanced childhood mature B-cell malignancies
- advanced childhood mature B-cell malignancies
- Japan Pediatric Leukemia/Lymphoma Study Group
- 2007-04-11
Other
- Phase II study of Irinotecan, TS-1 and Bevacizumab as second-line treatment in patients with advanced colorectal cancer (KMOG 0708)
- advanced colorectal cancer
- Kyushu Medical Oncology Group
- 2009-03-26